

NCIC CLINICAL TRIALS GROUP

MELANOMA

DISEASE SITE COMMITTEE MEETING AGENDA

DELTA CHELSEA HOTEL, TORONTO, ON

ROOM: SCOTT

MAY 1, 2011 – 9:30 AM – 11:15 AM

CHAIR: TERESA PETRELLA, ALAN SPATZ

(11:15 AM – 12:00 PM EXECUTIVE COMMITTEE MEETING – CLOSED)

8:00 – 9:30 am	<i>IND.202 Investigators Meeting</i>	
9:30 – 10:00 am	Welcome and Approval of Minutes	T. Petrella
	CME Reminder	
	TRIAL UPDATES:	
	• IND.189	T. Petrella
	• IND.202	T. Petrella
	• IND.202 miRs and FACS Data	A. Spatz
	EORTC Adjuvant Trial	T. Petrella / A. Spatz
10:00 – 10:15 am	BREAK	
10:15 – 10:45 am	NEW INITIATIVES:	
	Translational Research Initiative	T. Petrella / A. Spatz
	TRFI Melanoma Axis	A. Spatz
	ANZMTG WBRT Melanoma Phase III Study	T. Petrella
	BRAF+ IL21 Proposal	J. Monzon (CTG Fellow)
	A Phase II Study of Carbo/taxol and MK2206 (AKT inhibitor) in BRAF Negative Melanoma	A. Joshua
10:45 – 11:15 am	OTHER BUSINESS:	All
11:15 am	Meeting Adjourned	
11:15 am – 12:00 pm	<i>Executive Committee Meeting – Closed</i>	

The learning objectives for the Melanoma Disease Site Committee Open Meeting are as follows:

- To understand and address, through clinical and translational research, the disease burden associated with malignant melanoma in Canada
- To summarize recent developments in the understanding of molecular biology and therapeutics as these relate to malignant melanoma
- To cite and analyze recent results of clinical studies conducted by or in collaboration with NCIC Clinical Trials Group To understand and apply new clinical trial methodologies in the field of clinical research